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Objective: The conventional surgical repair and transcatheter closure of muscular ventricular septal defects are
known to have undesirable limitations. This communication describes the short-term results of perventricular de-
vice closure of muscular ventricular septal defects with the heart beating in 8 children with 15 muscular ventric-
ular septal defects, with or without other congenital malformations.
Methods: A subxiphoid minimally invasive incision was used in 3 children with isolated muscular ventricular
septal defects whereas standard full median sternotomies were used in the other 5 children who required subse-
quent correction of coexisting malformations. Under the continuous guidance of transesophageal echocardiogra-
phy, the free wall of the right ventricle was punctured, and a guidewire was introduced into the left ventricle
through the defect. A delivery sheath was advanced over the wire and through the defect into the left ventricle.
The device was released.
Results: A total of 14 muscular ventricular septal defects were successfully closed perventricularly without car-
diopulmonary bypass. There was no mortality perioperatively or during the entire follow-up period. At 6-month
follow-up, there was no detectable residual shunt, arrhythmia, or new mitral or tricuspid insufficiency. Other than
5 children with the coexisting malformations, none of the other children required any blood or blood products.
The average hospital stay was 7.9  2.2 days (range, 5–11 days).
Conclusion: Perventricular device closure of muscular ventricular septal defects with or without coexisting con-
genital malformations appeared to be safe and efficacious. The outcomes of short-term follow-up are acceptable.
Gan et al Congenital Heart DiseaseCDespite the fact that the results of conventional surgical repair
of muscular ventricular septal defects (MVSDs) with cardio-
pulmonary bypass (CPB) in terms of hospital mortality have
been steadily improving during recent years,1 the persistent
relatively high risk of postoperative residual shunt continues
to be of concern.2,3 During the surgical repair of MVSDs
with CPB and the heart arrested, one of the commonly en-
countered technical difficulties, despite extensive dissection
of the trabeculae, continues to be the difficulty in obtaining
adequate exposure and thus visualization of the MVSDs. In
2000, clinical experiencewith percutaneous transcatheter clo-
sure of single MVSDs with the Amplatzer occluder (AGA
Medical Corporation, Plymouth, Minn) was first described.4
However, this approach has limited applicability in young
children owing to the disparity between the sizes of the
sheaths and the patients’ access vessels. Several years later,
another report of 69 patients treated with this approach docu-
From the Departments of Thoracic and Cardiovascular Surgery,a Echocardiography,b
and Anesthesiology,c West China Hospital, Sichuan University, Chengdu, Sichuan,
People’s Republic of China.
Dr Changping Gan and Dr Ke Lin contributed equally to this article.
Supported in part by a grant (2006BAI01A08) from TheMinistry of Science and Tech-
nology of The People’s Republic of China.
Received for publication May 22, 2008; revisions received Aug 18, 2008; accepted for
publication Sept 1, 2008.
Address for reprints: Qi An,MD, Department of Thoracic and Cardiovascular Surgery,
West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of
China, 610041 (E-mail: anqi8890@163.com).
J Thorac Cardiovasc Surg 2009;137:929-33
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.09.010The Journal of Thoracic and Cmented a mortality of 2.9% and a major complication rate of
11%.5 Perventricular device closure (PVDC) of MVSDs on
the beating heart was first described in 1998 as another treat-
ment option,6 and this technique was refined in 2003 after
a consecutive series of 6 patients with encouraging results.7
This approach appears especially appealing for children
with multiple MVSDs or other associated congenital heart
diseases (CHDs) who may otherwise require a prolonged
CPB time with the subsequent complications. More recently,
early clinical experience with PVDC of nonmuscular VSDs
have been reported by us8 and another center.9 We herein de-
scribe our initial experience with PVDC of MVSDs in 8 chil-
drenwith either isolated singularMVSDormultipleMVSDs,
with or without other associated CHDs.
PATIENTS AND METHODS
Patients
BetweenMay and September of 2007, 8 children were admitted with the
diagnosis of either singular or multiple MVSDs that were of hemodynamic
significance. Five children also had associated CHDs. There were 4 boys
and 4 girls, with a mean age of 2.5  3.6 years (range, 0.5–11.0 years)
and a mean body weight of 10.9  7.6 kg (range, 5.5–27.5 kg). The use
of PVDC to treat MVSDs was approved by the hospital ethics committee
and individual consents were obtained from both parents of all the children
after all the pros and cons of the procedure were explained. Immediately be-
fore skin incision and under general anesthesia, all the children underwent
thorough transesophageal echocardiograms (TEEs) by the same echocardi-
ographer to confirm the preoperative transthoracic echocardiographic find-
ings, and the following data were recorded: (1) the dimension(s) of all the
MVSDs and the spatial relationship between the multiple MVSDs; (2) the
details, if any, of the associated CHDs. If the posterior rim of a defectardiovascular Surgery c Volume 137, Number 4 929
Congenital Heart Disease Gan et al
C
H
DAbbreviations and Acronyms
ASD ¼ atrial septal defect
CHD ¼ congenital heart disease
CPB ¼ cardiopulmonary bypass
LV ¼ left ventricular
MVSD ¼ muscular ventricular septal defect
PDA ¼ patent ductus arteriosus
PVDC ¼ perventricular device closure
PVSD ¼ perimembranous ventricular septal defect
RV ¼ right ventricular
TEE ¼ transesophageal echocardiogram
was too close to the tricuspid annulus or the anterior rim of a large anterior
defect was absent, we would not conduct a device closure. Three (37.5%)
children had a singular MVSD and 1 of them had associated CHDs. All
the other 5 (62.5%) children had multiple MVSDs with associated
CHDs. The mean diameter of the MVSDs was 4.9  2.4 mm (range, 2.0–
10.0 mm). None of the children had cardiac arrhythmia before surgery. Pa-
tient demographics, the dimensions and locations of the MVSDs, and the
associated CHDs are given in Table 1.
The Devices
There are two kinds of occluder (Shanghai Shape Memory Alloy Corpo-
ration, Shanghai, China): one is a muscular occluder and the other is a patent
ductus arteriosus (PDA) occluder (Figure 1). The basic characteristics of the
muscular occluder have been described before,10 but the flange of our de-
vice is 3 mm wider than the waist on the left ventricular (LV) side and 2
mm wider than the waist on the right ventricular (RV) side. The PDA oc-
cluder is similar to that in another study,11 and each occluder is designated
by the diameters of both the LV and RV waist.
Perventricular Technique
In the child with isolated MVSDs and no CPB anticipated, a subxiphoid
3- to 4-cm skin incision was made followed by a lower partial sternotomy.
The pericardium was partially and longitudinally incised and suspended for
adequate exposure. In the other children with associated CHDs, conven-
tional full median sternotomies were used. With the heart beating and under
continuous TEE guidance, the RV free wall was gently depressed with the
surgeon’s index finger. The depression on the RV free wall was easily visu-
alized by TEE. By changing the location of the depression, we could deter-
mine a point on the RV free wall that was nearest to the defect to be occluded
and yet preserve adequate distance and space to allow manipulation of the
guidewire, sheath, and release of the device. The following technique was
similar to that in another research report.7 If a PDA occluder was used,
the LV disc was similarly released first, followed by the release of the waist.
The appropriate device size was chosen to be 1 to 2 mm larger than the de-
fect size. If a single device was selected to close 2 nearby defects simulta-
neously, the diameter of its left disc should just cover the 2 VSDs. At this
point, the echocardiographer would carefully look for any residual shunt
or new mitral or tricuspid regurgitation. If none was found, the device
was released. If the child had associated CHDs that needed open cardiac re-
pair, CPB was established in the usual fashion and the CHDs were closed
accordingly. All the children received broad-spectrum second-generation
cephalosporin for 3 days. Aspirin (3 mg/kg) was started on postoperative
day 2 and continued for 6 months.
Follow-up
At discharge and 6-month follow-up, all the children underwent trans-
thoracic echocardiographic examination by the same echocardiographer.930 The Journal of Thoracic and Cardiovascular SurSpecific attention was paid to look for any residual shunt and new mitral
and tricuspid regurgitation. Twelve-lead electrocardiograms were also ob-
tained at the same time to detect any arrhythmia.
RESULTS
Fourteen (93%) of 15 MVSDs were successfully closed
without CPB. Eleven MVSDs were closed by muscular oc-
cluders and 3 MVSDs were closed by PDA occluders.
Singular MVSD
Three children with singular MVSD successfully under-
went PVDC with 8-mm, 10-mm, and 10-mm devices for
their 7-mm, 8-mm, and 8-mm defects, respectively. There
was no detectable residual shunt or any new mitral or tricus-
pid regurgitation by TEE after the releases of the devices.
The child with associated CHDs (patient 1, Table 1) also un-
derwent uneventful repair of her CHDs with CPB.
Multiple MVSDs
In the child with a 10-mm anterior MVSD and a 6-mm
apical MVSD (patient 4, Table 1), we closed the anterior de-
fect with a 12-mm device uneventfully. We then used an-
other RV free wall puncture site to establish a second
pathway closer to the apex to close the apical MVSD
(Figure 2). Since we anticipated that the RV apex would
not have enough space to accommodate the regular occluder,
we elected instead to use an 8/6-mm PDA occluder, which
did not have an RV disc. The associated secundum type
6-mm atrial septal defect (ASD) was successfully closed
with an 8-mm ASD occluder (Shanghai Shape Memory Al-
loy Corporation) via a right atrial puncture site (Figure 3).
Another child (patient 5, Table 1) had 2 apical MVSDs,
a large PDA, and a perimembranous VSD (PVSD). We at-
tempted unsuccessfully to use the regular MVSD occluders
to close these 2 apical MVSDs owing to the limited space
at the apex, making opening the RV disc of the regular
occluder impossible. We therefore switched to using two
8/6-mm and 6/4-mm PDA occluders to successfully close
the 6-mm and 4-mm apical MVSDs. Immediate TEE exam-
ination did not detect any residual shunt. CPB was then es-
tablished and the large PDA was ligated before cardioplegic
arrest and repair of the PVSD.
In the child with 2 relatively small MVSDs that were only
3-mm apart, as well as a nonrestrictive PVSD (patient 6, Ta-
ble 1), we closed the 4-mm posterior MVSD with a 6-mm
occluder relatively easily and immediate TEE examination
did not show any residual shunt. The nearby 2-mm MVSD
was also reduced to a 0.5-mm defect. Owing to the small
size of this defect and its close proximity to the occluder
of the first defect, we were unable to pass the guidewire
into the LV cavity after multiple attempts. We then accu-
rately established the spatial relationship between this small
defect and the first occluder before establishing CPB and
closing this defect with pledget-supported 4-0 Prolenegery c April 2009
Gan et al Congenital Heart DiseaseTABLE 1. Characteristics of the patients, MVSDs, and associated CHDs
Diameter (mm)/location of MVSDs (Size [mm]/type of device)
Patient
No.
Gender
(M/F) Age (y)
Weight
(kg) MVSD1 MVSD2 MVSD3 MVSD4 Associated CHDs
1 F 8/12 8 7/middle (8/MO) — — — PAPVC, ASD (posterior,
12 mm), PVSD (12
mm), TR (moderate)
2 M 6/12 5.5 8/middle (10/MO) — — — —
3 M 10/12 8 8/middle (10/MO) — — — —
4 F 9/12 6 10/anterior (12/MO) 6/apical
(8-6/PDAO)
— — ASD (ostium secundum,
6 mm)
5 F 19/12 9.5 6/apical (8-6/ PDAO) 4/apical
(6-4/PDAO)
— — PDA (103 8 mm), PVSD
(15 mm)
6 M 11 27.5 4/posterior (6/MO) 2/posterior — — PVSD (25 mm), TR (mild)
7 M 4 17 3/middle (6/MO) 3/middle (6/MO) — — —
8 F 9/12 6 3.5/anterior (7/MO) 3.5/anterior (7/MO) 3/middle
(5/MO)
3/posterior
(5/MO)
ASD (ostium secundum,
12 mm)
ASD, Atrial septal defect; CHDs, congenital heart diseases; F, female; M, male; MO, muscular occluder; MVSD, muscular ventricular septal defect; PAPVC, partial anomalous
pulmonary venous connection; PDA, patent ductus arteriosus; PDAO, patent ductus arteriosus occluder; PVSD, perimembranous ventricular septal defect; TR, tricuspid regurgi-
tation.C
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Dpolypropylene suture (Ethicon, Inc, Somerville, NJ) through
the tricuspid valve. The coexisting PVSD was closed in the
usual fashion with a patch.
In another child (patient 7, Table 1) with two 3-mm large
MVSDs that were 3-mm apart, we closed the defects with
a single 6-mm occluder. The last girl (patient 8, Table 1)
had 4 MVSDs and an ASD. We closed the 2 nearby anterior
MVSDs with a single occluder and closed the middle and
posterior MVSDs with two 5-mm occluders. Her ASD
was also closed peratrially with a 12-mm ASD occluder
FIGURE 1. Top, The muscular occluder with the flange that is 3 mmwider
than the waist on the left ventricular side and 2 mm wider than the waist on
the right ventricular side.Bottom,The patent ductus arteriosus occluder with
a 5-mm–tall isosceles trapezoid sagittal section and its left ventricular
flange, which is 2 mm wider than the waist on the left ventricular side.The Journal of Thoracic and C(Shanghai Shape Memory Alloy Corporation). TEE showed
all 6 MVSDs were closed successfully and no residual shunt
was detected.
At discharge and 6-month follow-up, there was no detect-
able residual shunt or any closure-related new mitral or tri-
cuspid regurgitation or exacerbation of any pre-existing
regurgitation. All the occluders appeared to be in good posi-
tions, and no arrhythmia was noticed. There was no mortal-
ity during the hospital stay or during the follow-up period.
Three children who required CPB to repair the associated
CHDs and 2 children who received multiple devices needed
blood transfusion; the other 3 children did not require any
blood or blood product transfusion. The average hospital
stay was 7.9  2.2 days (range, 5–11 days).
FIGURE 2. Another sheath was established through the apical defect after
an anterior defect had been closed. LV, Left ventricle; MO, muscular oc-
cluder; RV, right ventricle; S, sheath.ardiovascular Surgery c Volume 137, Number 4 931
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DDISCUSSION
MVSD can be singular or multiple. At its extreme form, it
can present as ‘‘Swiss cheese’’ type.12 When MVSDs be-
come hemodynamically significant, especially when they
are associated with other CHDs, early intervention is indi-
cated. Owing to the unique locations of some of theMVSDs,
especially those in the apical or anterior region of the ven-
tricular septum, direct surgical repair with CPB and cardio-
plegic arrest can present significant difficulties. A right
ventriculotomy will impair the long-term RV function and
increase the likelihood of arrhythmia,13 but it can never
guarantee a good exposure. Once inside the RV, the exten-
sive trabeculation of the RV cavity makes either direct suture
or patch closure technically challenging and more prone to
result in residual shunt. Recent reports from a highly experi-
enced center also attested to the challenging nature of surgi-
cal repair of MVSDs.14,15 The advent of the transcatheter
approach provided a minimally invasive option for this dis-
ease process. However, this approach has limited applicabil-
ity in young children owing to the disparity between the
sizes of the sheaths and the devices required and the access
vessels.5,16 On the contrary, PVDC of VSDs is almost not
affected by the patient’s age, body weight, or dimensions
of the VSDs. In this study, we successfully closed an 8-mm
MVSD in a 6-month-old boy who weighed only 5.5 kg
and might have presented an overwhelming technical chal-
lenge to the transcatheter approach, let alone the prolonged
radiation exposure with all its deleterious long-term effects.
PVDC, on the other hand, uses strictly TEE for intraopera-
tive control and thus avoids all the radiation. Compared
with the conventional repair with CPB, PVDC with TEE
control provides immediate and real-time assessment of
the effects of the devices on valve functions, the presence
of any residual shunt, and, if necessary, timely corrective
FIGURE 3. Three occluders were shown in one section, and the Doppler
test showed no residual shunt between the two atria. ASDO, Atrial septal
defect occluder; MO, muscular occluder; PDAO, patent ductus arteriosus
occluder.932 The Journal of Thoracic and Cardiovascular Surmeasures. On the other hand, the surgeon doing a conven-
tional repair with CPB would have to wait until the child
is weaned from CPB before an accurate assessment of his re-
pair with TEE can be obtained. In the case of any residual
shunt, return to CPB is inevitable and time consuming.
Many studies have pointed out the adverse effects of CPB
in general and specifically on the development of the brain
in children.17,18 More recent studies also documented that
the perioperative mortality and morbidity can be improved
if CPB is avoided.19 From this point of view, PVDC of
VSDs not only can eliminate the side effects of CPB alto-
gether if the child has no other associated CHDs, but can
also markedly reduce the CPB time if the child does have
other associated CHDs and also reduce the risk of postoper-
ative residual shunt.
Our experience with the child (patient 6, Table 1) who had
2 small nearby MVSDs might have suggested that after the
larger defect was closed with a device, the nearby smaller
defect might become even smaller, making it difficult to
pass the guidewire to the LV cavity to establish another path-
way for the deployment of the second device. This might be
due to the following: (1) the waist of the already inserted de-
vice might be compressing the muscle bridge between the 2
defects, thus effectively narrowing the diameter of the un-
closed defect, and (2) the flanges of the in-site device might
be partially covering up the nearby defect. If this occurs, it
might be easier to close it with the aid of CPB, especially
if there are other associated CHDs that require CPB for cor-
rection after an accurate assessment of the orientation of the
residual defect with respect to the device has been estab-
lished. The idea of using a bigger than necessary device to
attempt to close 2 nearby small MVSDs is certainly tempt-
ing, and our experience with 2 cases has proved the feasibil-
ity. Our initial experience also suggested that PDA occluders
can be effectively used to close apical MVSDs when the ge-
ography of the apex makes it difficult or impossible to de-
ploy the regular bi-disc occluder.
In conclusion, PVDC appeared to be a safe, effective, and
less invasive option for the treatment of either singular or
multiple MVSDs, with or without associated CHDs. The re-
sults of the 6-month follow-up, in terms of stability of the de-
vices, residual shunt, closure-related valve dysfunction, and
new arrhythmia, are satisfactory. However, the conclusion
derived from our experience is limited owing to the small
size of the patients. Further studies with more patients and
longer term follow-ups will be required to truly confirm the
role of PVDCas an established formof treatment forMVSDs.
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